Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Insights - Agios is at a pivotal growth inflection point, driven by three key components [3] - The PK activator franchise is advancing as the standard of care for various hemolytic anemias, establishing Agios's leadership in rare hematology [3] - The company is progressing its early and mid-stage pipeline, which has the potential to unlock further value [4] - Recent approval for thalassemia provides a clear path to profitability with existing products [4]